MicroRNA-194: a novel regulator of glucagon-like peptide-1 synthesis in intestinal L cells

Jiao Wang1, Di Zhao1, Cheng-Zhi Ding2, Feng Guo1, Li-Na Wu1, Feng-Jiao Huang1, Yan-Ling Liu1, Shui-Ying Zhao1, Ying Xin1, Sheng-Nan Ma1, Hong-Fei Ji1, Xiang Wang1 and Li-Rui Wei1

Abstract
In the status of obesity, the glucagon-like peptide-1 (GLP-1) level usually declines and results in metabolic syndrome. This study aimed to investigate the intracellular mechanism of GLP-1 synthesis in L cells from the perspective of microRNA (miRNA). In the present study, we found that GLP-1 level was down-regulated in the plasma and ileum tissues of obese mice, while the ileac miR-194 expression was up-regulated. In vitro experiments indicated that miR-194 overexpression down-regulated GLP-1 level, mRNA levels of proglucagon gene (gcg) and prohormone convertase 1/3 gene (pcsk1), and the nuclear protein level of beta-catenin (β-catenin). Further investigation confirmed that β-catenin could promote gcg transcription through binding to transcription factor 7-like 2 (TCF7L2). miR-194 suppressed gcg mRNA level via negatively regulating TCF7L2 expression. What’s more, forkhead box a1 (Foxa1) could bind to the promoter of pcks1 and enhanced its transcription. miR-194 suppressed pcks1 transcription through targeting Foxa1. Besides, the interference of miR-194 reduced palmitate (PA)-induced cell apoptosis and the anti-apoptosis effect of miR-194 inhibitor was abolished by TCF7L2 knockdown. Finally, in HFD-induced obese mice, the silence of miR-194 significantly elevated GLP-1 level and improved the metabolic symptoms caused by GLP-1 deficiency. To sum up, our study found that miR-194 suppressed GLP-1 synthesis in L cells via inhibiting TCF7L2-mediated gcg transcription and Foxa1-mediated pcks1 transcription. Meanwhile, miR-194 took part in the PA-induced apoptosis of L cells.

Introduction
Over the last several decades, obesity has become a global epidemic due to overeating and lack of exercise. According to statistics, about 700 million people in the world are suffered from obesity1. Generally, obesity is accompanied by metabolic disturbances (such as dyslipidemia, hyperglycemia, and hypertension) and obese individuals are more prone to cancer and heart disease2. Although lifestyle interventions, involving diet and physical activity, are cornerstones for obesity management, the use of pharmaceutical agents is indispensable for the long-term treatment of obesity.

Glucagon-like peptide 1 (GLP-1), a gut hormone mainly secreted by intestinal L cells, has been reported to be an essential regulator in glucose metabolism via stimulating insulin secretion and inhibiting glucagon release3. Since GLP-1 could effectively improve insulin resistance, induce satiety, and suppress appetite, it is considered as a promising hormone for treating metabolic syndrome caused by obesity4. There are two essential participants in the progress of GLP-1 production, proglucagon gene (gcg) and prohormone convertase 1/3 (PC1/3). Under normal conditions, in intestinal L cells, gcg codes for proglucagon, then, the proglucagon is hydrolyzed to GLP-1 in the presence of PC1/35. However, under the stimulation of a high-fat diet (HFD), the intestinal L cell function was impaired and the mRNA levels of gcg and pcks1 (the gene of PC1/3) were down-regulated, resulting in the defective GLP-1 production6–8. However, the specific mechanism of HFD impairing the GLP-1 production which was mediated by gcg and PC1/3 remains perplexing.
MicroRNA (miRNA) is a class of 19-24 nucleotides non-coding RNA and its dysregulation has been observed in the occurrence of obesity. Olivo-Marston et al. screened out eighteen miRNAs which were abnormally expressed in the colons of HFD-induced obese mice utilizing microarray, among them, the miR-194 level was significantly increased. In addition, the high expression of miR-194 aggravated cardiac injury and mitochondrial dysfunction in obese mice. The interference of miR-194 favored the recovery of dietary-induced non-alcoholic fatty liver disease by reducing the inflammatory response. The above researches indicated that miR-194 has been implicated to play a role in obesity, while whether miR-194 affects GLP-1 production during obesity is still unknown.

It is known that obese individuals frequently exhibit elevated levels of interleukin 6 (IL-6) and free fatty acid (FFA) as an enteroendocrine cell mainly located in the distal ileum and colon, L cells can sense the cytokines and luminal nutrients, and transform these pieces of information into stimulation of GLP-1 secretion. As reported, in the obese mice, the plasma IL-6 level was elevated and the high level of IL-6 increased GLP-1 synthesis and secretion in intestinal L cells via promoting gcg transcription. Meanwhile, as the most abundant saturated FFA, palmitate (PA) was cumulated in the large intestine of obese mice and the PA treatment contributed to the apoptosis of intestinal L cells in vitro. The above data hinting that L cells could be affected by IL-6 and PA during obesity. What’s more, previous studies reported that miR-194 was down-regulated by IL-6 in nucleus pulposus cells while up-regulated by PA in hepatoma cell line HepG2. Inspired by the previous studies, we speculated that miR-194 might be involved in the regulatory effect of IL-6 and PA on GLP-1 synthesis during obesity.

Herein in this study, we investigated the specific modulatory mechanisms of miR-194 on the secretion of GLP-1 in intestinal L cells under the HFD stimulation, hoping to provide new intervention targets for the deficiency of GLP-1 secretion in obesity.

Materials and methods

Animal experiments

Six-week-old male C57BL/6 mice (n = 30, Shanghai SLAC Laboratory Animal Co., Ltd, China) were divided into two groups. In the control group (n = 15), mice were fed with a normal chow diet (D12450H, Research Diets, USA). In the HFD group (n = 15), mice were fed with a 60% high-fat diet (D12492, Research Diets, USA). Twelve weeks later, the feces of mice were collected and the contents of PA were detected using chromatography. Blood samples were obtained for the measurement of total cholesterol (TG), triglyceride (TC), glucose, and IL-6 levels using an automatic biochemistry analyzer (BECKMAN, USA) or a Mouse IL-6 ELISA Kit (Abcam, UK), respectively. Adipose, pancreatic, and ileum tissues were collected for the follow-up experiments.

To examine the effect of miR-194 inhibition on HFD mice, six-week-old male C57BL/6 mice were divided into four groups: control (n = 6), HFD (n = 6), HFD + miR-194 antagonir (n = 6), and HFD + negative control of miR-194 antagonir (antagomir NC, n = 6). In HFD + miR-194 antagonir and HFD + antagonir NC group, after 8 weeks of HFD, mice were treated with miR-194 antagonir or antagonir NC as previously described. Briefly, mice were anesthetized using pentobarbital sodium (50 mg/kg). Then, intracolonc enemas were performed using a 3.5 cm long polyethylene cannula (Intramedic PE-20 tubing, Becton Dickinson, USA) attached to an insulin syringe and introduced into the colon reaching ~3 cm from the anus. miR-194 antagonir or antagonir NC (10 mg/kg) was instilled into the colon using a 1 ml syringe. Mice were then returned to the cages and continued to be fed with HFD. The intracolonc enemas were performed once a week. Four weeks later, the mice were sacrificed. Blood samples were obtained for the measurement of TG, TC, and IL-6 levels. Adipose, pancreatic, ileum, and colon tissues were collected for the follow-up experiments. The animal was chosen and group-dividing randomly and the investigators were blinded to the group allocation. All animal procedures were in accordance with institutional guidelines and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

Cell culture and transfection

An L-like cell line, STC-1, were purchased from Cell Bank of Type Culture Collection of the Shanghai Institute of Cell Biology (China), authenticated and tested for mycoplasma contamination from the Procell (China), and maintained in Dulbecco’s modified eagle medium (DMEM; ATCC, USA) containing 10% fetal bovine serum (GIBCO, USA) with 5% CO2 at 37°C. RNAi vector (miR-194 inhibitor, si-ctnnb1, si-psk1, si-TCF7L2, and si-Foxa1), over-expression vectors (miR-194 mimic) and relative negative controls (NC, si-NC, and miRN) were synthesized by RIBOBIO (China). For transfection, cells were seeded in 6-well plates with a concentration of 4 × 10⁵ cells/well. When the cells were cultured to 70% confluence, cells were incubated with 2 ml Opti-MEM medium (GIBCO, USA) containing plasmids (1 μg) and Lipofectamine 3000 (2.5 μl; Invitrogen, USA). Six hours later, the original medium was replaced with 2 ml fresh DMEM complete medium. Eighteen hours later, cells were incubated with different concentrations of IL-6 or PA for another 24 h. The sequences of the transfected components were shown in Table 1.
Table 1 Sequences of the transfected components used in the experiments.

| Transfected components | Sequences |
|------------------------|-----------|
| Si-NC                  | 5'-UUCCGGAGCUUGAGAAGGCUU-3' |
| Si-TCF7L2              | 5'-CGAAGUUCGGGAGGAGGCUU-3' |
| Si-Ctnmb1              | 5'-GGGUGCCAUUCCCAAGCUU-3' |
| Si-PcSK1               | 5'-CAAGUCAGCUUGAAGGCUU-3' |
| Si-Foxa1               | 5'-AGCACAAGCUGGACUUAAGG-3' |
| miR-194 inhibitor      | 5'-TCTCATGTGAGTGTCGTGTTACA-3' |
| NC                     | 5'-AGGUTCAACUTGAGTACAGGA-3' |
| miR-194 mimic          | 5'-UCGAGCAGCUUUGCAGATGTCTC-3' |
| miRNC                  | 5'-ACATTGTCCGTTGAGGTACACCT-3' |

Quantitative real-time PCR (qRT-PCR)

Total RNA was extracted from cells and tissues of mice using TRIZOL reagent (Invitrogen, USA). The concentration and purity of RNA were measured by the ultraviolet spectrophotometer. Reverse transcription was conducted for the synthesis of cDNA using the SuperScript IV First-Strand Synthesis System (Invitrogen, USA) or miScript Reverse Transcription kit (QIAGEN, Germany). The qRT-PCR assay was conducted using the Platinum Quantitative RT-PCR ThermoScript One-Step Kit (Invitrogen, USA) or miScript SYBR Green PCR kit (QIAGEN, Germany) in ABI 7500 Real-Time PCR System (Applied Biosystems, CA, USA). U6 or GAPDH was used as the endogenous control. The sequences of qRT-PCR primers were shown in Table 2.

Western blot

Western blot was performed as previously described19. Whole-cell protein samples were purified using RIPA lysis buffer (Cwbio, China) and the nuclear protein samples were purified using a Nucleoprotein Extraction Kit (Sangon Biotech, China). The primary antibodies used in the experiment were as follows: anti-PC1/3 (1:1000), anti-beta-catenin (β-catenin; 1:5000), anti-transcription factor 7-like 2 (TCF7L2; 1:25000), anti-forkhead box a1 (Foxa1; 1:1000), anti-cleaved-caspase 3 (c-caspase 3; 1:500), anti-beta-actin (1:5000), and anti-Lamin B1 (0.1 µg/ml) (all purchased from Abcam, UK). The secondary antibody used in the experiment was Goat Anti-Rabbit IgG H&L (1:5000; Abcam, UK).

Measurements of GLP-1 in plasma and culture medium

Plasma samples of mice were collected after anesthesia in the presence of aprotinin (2 µg/ml), EDTA (1 mg/ml), and diprotin (0.1 mM). GLP-1 (active) level was measured using a Mouse GLP-1 Elisa Kit (Solarbio, China) according to the manufacturer’s instruction.

Cell culture medium was collected in the presence of hact protease and phosphatase inhibitor cocktail (10 µl/ml, to suppress the degradation of GLP-1; Thermo Fisher Scientific, USA).

Dual-luciferase reporter assay

To verify the combination between miR-194 and TCF7L2, the sequence of TCF7L2 3’UTR was amplified and inserted into a pmirGLO vector (Promega, USA). 0.5 µg plasmid containing TCF7L2 3’UTR and 20 nM miR-194 mimic/miRNC were cotransfected into well-grown STC-1 cells by using lipofectamine 2000 (ThermoFisher, USA). Forty-eight hours after transfection, cells were lysed and the luciferase activity was measured by dual-luciferase reporter assay system (Promega, USA). To verify the combination between miR-194 and Foxa1, the luciferase activity of Foxa1 3’UTR was measured in the same way. The primer sequences for amplifying TCF7L2/ Foxa1 3’UTR were shown in Table 2.

To measured the prompter activity of ggc, the sequence of ggc promoter was amplified and inserted into pGL3-basic plasmids (Promega, USA). Cells were then cotransfected with pGL3-basic plasmid containing ggc promoter + si-TCF7L2 + pcDNA-β-catenin/ pcDNA empty vector using lipofectamine 2000 (ThermoFisher, USA). Forty-eight hours later, the luciferase activity was measured by the dual-luciferase reporter assay system (Promega, USA). To verify the promoter activity of pcsk1, the luciferase activity of the pcsk1 promoter was measured in the same way. The primer sequences for amplifying ggc/pcsk1 promoters were shown in Table 2.

Co-immunoprecipitation (Co-IP)

Co-IP was performed as previously described20. Briefly, protein lysates from 4 × 10^7 STC-1 cells which were transfected with miR-194 inhibitor or NC were incubated with anti-TCF7L2 antibody (Abcam, USA). Twelve hours later, cells were incubated with Protein A/G PLUS agarose resin (Yeasen, China). The complexes were washed three times with washing buffer. The beads were then eluted and subjected to reverse crosslinking. The beads were then eluted and subjected to reverse crosslinking. Then, the complex was assessed by qRT-PCR. For qRT-PCR, the primer of the pcsk1 promoter was synthesized by RIBOBIO (China). The sequences of pcsk1 promoters: F 5’-TACACAAACACACGTGTCG-3’; R 5’-CCTAAAGGGAGTGGGAGGTG-3’.

Chromatin immunoprecipitation (CHIP)

The combination of Foxa1 and pcsk1 promoter was assessed using the ChiP-IT Kit (Active Motif, USA) according to the manufacturer’s instructions. Briefly, anti-Foxa1 antibody-coated beads were used to pull down the Foxa1 complexes from 1 × 10^7 STC-1 cells. The beads were washed three times with washing buffer. The beads were then eluted and subjected to reverse crosslinking. Then, the complex was assessed by qRT-PCR. For qRT-PCR, the primer of the pcsk1 promoter was synthesized by RIBOBIO (China). The sequences of pcsk1 promoters: F 5’-TACACAAACACACGTGTCG-3’; R 5’-CCTAAAGGGAGTGGGAGGTG-3’.
Cell viability assay
The cell viability was assessed by methyl thiazolyl tetrazolium (MTT) assay. Cells were seeded in 6-well plates with a concentration of $4 \times 10^5$ cells/well. When the cells were cultured to 70% confluence, the cells of each well were incubated with 10 $\mu$l MTT (Cwbio, China) at 37 °C in the dark. Four hours later, the supernatant was removed and formazan crystals were dissolved by the addition of dimethyl sulfoxide (DMSO, 150 $\mu$l/well; Cwbio, China) at 37 °C for 15 min. The absorbance intensity was measured at 490 nm.

$$\text{Cell viability (\%)} = \frac{\text{mean absorbance in test wells}}{\text{mean absorbance in control wells}} \times 100.$$ 

Cell apoptosis assay
Cells were seeded in 6-well plates at $4 \times 10^5$ cells/well. When the cells were cultured to 70% confluence, cells were collected and washed with PBS. Cell apoptosis was measured using the Annexin V-FITC Apoptosis Detection Kit (Univ-bio, China). In brief, cells were resuspended in 195 $\mu$l Annexin V-EGFP Binding Buffer and incubated with 5 $\mu$l Annexin V-FITC for 15 min at room temperature in the dark. Then, 10 $\mu$l Propidium Iodide Staining Solution was added to the cells. Five minutes later, cell apoptosis was measured by the flow cytometer (BD, USA) immediately.

### Table 2 Sequences of the primers used in the experiments.

| qRT-PCR Primers | Sequences |
|-----------------|-----------|
| miR-194         | RT-Primer |
|                 | 5'-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCACA-3' |
|                 | R: 5'-AGTGCAGGGTCCAGGATT-3' |
| gcg             | F: 5'-CGTGCCCAAGATTTTGTCGA-3' |
|                 | R: 5'-CCCTTACAGCATGGCTCTCAA-3' |
| pcsk1           | F: 5'-GCTCCATCTTTCTTGCGCT-3' |
|                 | R: 5'-ACTGCTGTAAGGGTGAGCCA-3' |
| Sox17           | F: 5'-GTCCTAGCTCGGACTATGC-3' |
|                 | R: 5'-CCGTAGTAGGTCCAGAGC-3' |
| Chd8            | F: 5'-TTCACTCTGCCTGGCGTCT-3' |
| U6              | F: 5'-AAGCCCAACTCAAC-3' |
|                 | R: 5'-ACCGTTCCAGAATTTGCGT-3' |
| GAPDH           | F: 5'-TCACTCAAGATGGTCAGC-3' |
|                 | R: 5'-AGATCCACGAGGACACATT-3' |

| 3'UTR primers   | Sequences |
|-----------------|-----------|
| TC7F2           | F: 5'-CGAGCTCcctttgaccccttagtca(Sacl)-3' |
|                 | R: 5'-GCTCTAGAgtgctttgacagctgtg(XbaI)-3' |
| Foxa1           | F: 5'-CGAGCTCacacagagacacacacacacca(Sacl)-3' |
|                 | R: 5'-GCTCTAGAagggagaaaggggaggaag(XbaI)-3' |

| Promoter primers | Sequences |
|------------------|-----------|
| gcg              | F: 5'-CGAGCTCacatgcctaccaccct(Sacl)-3' |
|                 | R: 5'-GGCTAGCctaccaccct(Sacl)-3' |
| pcsk1            | -2.2K F: 5'-CGAGCTCctattccaaaacaccttctgc(Sacl)-3' |
|                 | -1.5K F: 5'-CGACCTCCctacggttcagtgagagac(Sacl)-3' |
|                 | -0.8K F: 5'-CGAGCTCgcccaggttcagtgagagac(Sacl)-3' |
|                 | R: 5'-CGAGCTCgcccaggttcagtgagagac(Sacl)-3' |

Wang et al. Cell Death and Disease (2021) 12:113
Page 4 of 14
Official journal of the Cell Death Differentiation Association
Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT)

After feeding with a normal chow diet or HFD for 12 weeks, mice received OGTT and ITT. For OGTT, after a 12-hour fast, mice were gavaged with glucose (3 g/kg body weight). For ITT, after a 4-hour fast, mice received an intraperitoneal injection of insulin (0.75 U/kg). Blood samples were taken from the tail vein at 0, 15, 30, 60, 90, and 120 min after administration of glucose or insulin. Plasma glucose levels were measured by Glucotrend (Roche, GER) and plasma insulin levels were measured using the Insulin Mouse ELISA Kit (Invitrogen, USA).

H&E staining

Adipose and pancreatic tissues were fixed in 4% formaldehyde, embedded with paraffin and sectioned, following hematoxylin and eosin staining. The sections were then visualized under the microscope (Nikon, USA) and the areas of adipocytes were analyzed using Image Pro-Plus.

Immunohistochemistry

Ileum and colon tissues were fixed in 4% formaldehyde, embedded with paraffin and sectioned. Antigen retrieval was performed using proteinase K (Solarbio, China) and endogenous peroxidase activity was deactivated using 3% H2O2. Then, sections were blocked with 5% bovine serum albumin (BSA; Solarbio, China) and incubated with primary antibody against GLP-1 (1:500; Abcam, UK) overnight. Then, sections were incubated with the secondary antibody and ABC solution (Solarbio, China). After the diaminobenzidine solution and hematoxylin staining, sections were mounted and visualized under the microscope (Nikon, USA). The GLP-1 positive cells per high-power field (HPF) were calculated in 10 random HPFs.

Statistical analysis

SPSS 18.0 software was used for data analysis. Measurement data were expressed as mean±standard deviation (SD). Data were analyzed by student’s t-test (for two experimental groups) or one-way ANOVA (for multiple experimental groups). The significance was set at P<0.05.

Results

miR-194 was up-regulated in HFD-induced obese mice

C57BL/6 mice were fed with a normal chow diet or HFD for 12 weeks. As shown in Supplemental Fig. 1a–d, compared with the control group, the HFD group displayed an apparent weight gain, higher plasma levels of TG, TC, and glucose, and increased areas of adipocyte and islet, confirming that HFD successfully induced the obesity in mice. Moreover, in response to HFD, the GLP-1 expression was down-regulated in both ileum tissues and plasma samples (Fig. 1a and b) while the ileac miR-194 expression was up-regulated (Fig. 1c). Then, the further Pearson correlation analysis demonstrated a negative correlation (r = −0.544, P<0.05) between plasma GLP-1 level and ileac miR-194 expression (Fig. 1d).

miR-194 overexpression suppressed the GLP-1 synthesis in an L-like cell line

As shown in Fig. 2a, the HFD group exhibited a significantly higher plasma level of IL-6 than that of the control group. Meanwhile, the results of in vitro experiments showed that IL-6 could elevate GLP-1 level and the mRNA levels of gcg and pcsk1 (two essential genes relevant to GLP-1 production5) in a dose-dependent way (Fig. 2b and d), confirming that IL-6 was a promoter for GLP-1 synthesis. Besides, the results of Fig. 2c showed that IL-6 negatively regulated the miR-194 expression. Further experiments depicted that miR-194 overexpression could reduce GLP-1 level, suppress transcriptions of gcg and pcsk1, and inhibit PC1/3 expression in untreated STC-1 cells (Fig. 2h–j), validated that miR-194 was a regulator of GLP-1 production in intestinal L cells. To explore whether IL-6 promoting GLP-1 synthesis via suppressing miR-194 expression, we overexpressed miR-194 in STC-1 cells utilizing miR-194 mimic (50 nM). Interestingly, in IL-6-treated STC-1 cells, the overexpression of miR-194 reduced the IL-6-induced GLP-1 secretion (Fig. 2e), abolished the promoting effect of IL-6 on the mRNA levels of gcg and pcsk1 and the protein level of PC1/3 (Fig. 2f and g). The previous study showed that the transcriptional activation of gcg could be promoted by Wnt/β-catenin signaling pathway21. Indeed, the nuclear expression of β-catenin was accumulated (the marker of Wnt/β-catenin signaling activation22) in IL-6-treated cells, while the overexpression of miR-194 abrogated the effect of IL-6 (Fig. 2g). Similarly, in miR-194-overexpressed STC-1 cells, the nuclear expression of β-catenin was reduced (Fig. 2i). These data indicating that the Wnt/β-catenin signaling was involved in the regulatory effect of IL-6/miR-194 on ggc transcription.

miR-194 reduced GLP-1 synthesis via repressing TCF7L2-mediated ggc transcription

In IL-6-treated STC-1 cells which were transfected with si-RNA targeting ctnnb1 (the encoding gene of β-catenin), the silence of β-catenin notably decreased GLP-1 level and ggc transcription, while not affecting the pcsk1 transcription (Fig. 3a), indicating that β-catenin elevating GLP-1 level via facilitating ggc transcription. In STC-1 cells cotransfected with pcDNA-β-catenin+si-PCSK1, though the mRNA level of ggc was elevated by pcDNA-β-catenin, si-PCSK1 could remove the promoting effect of pcDNA-β-catenin on GLP-1 level (Fig. 3b). The above data hinted that both ggc transcription and PC1/3 expression were indispensable for the synthesis of GLP-1.
Firstly, we investigated the mechanism of miR-194 reducing GLP-1 production from the perspective of gcg transcription. Considering that miR-194 mimic reduced the nuclear accumulation of β-catenin (Fig. 2j), we speculated that miR-194 inhibited gcg transcription via regulating the Wnt/β-catenin signaling pathway. Using bioinformatics software (TargetScan and micro T-CDS), we screened out 191 common target genes of miR-194 (Supplementary Fig. 2a). Then, using the KEGG pathway analysis, we determined 6 potential target genes [calmodulin-dependent protein kinase II gamma(CAMK2G), protein phosphatase 3 regulatory subunit B, alpha (PPP3R1), sex-determining region Y-box 17 (SOX17), transcription factor-7-like 2 (TCF7L2), chromodomain helicase DNA-binding protein 8 (CHD8), and disheveled associated activator of morphogenesis 1 (DAAM1)] of miR-194 which were correlated to the Wnt pathway (Supplementary Fig. 2b). Among them, CAMK2G, PPP3R1, and DAAM1 are correlated to non-canonical Wnt signaling, while SOX17, TCF7L2, and CHD8 are correlated to canonical Wnt/β-catenin signaling. Therefore, we measured the levels of SOX17, TCF7L2, and CHD8 in STC-1 cells which were transfected with miR-194 mimic. As shown in Fig. 3, only the mRNA level of TCF7L2 exhibited a significantly down-regulation in response to the miR-194 mimic transfection. Subsequently, the luciferase gene reporter assay confirmed that miR-194 mimic suppressed the luciferase activity of TCF7L2 3'UTR and the results of western blot showed that miR-194 mimic negatively regulated TCF7L2 expression (Fig. 3d). As depicted in Fig. e–f, the interference of TCF7L2 removed the promoting effect of β-catenin over-expression on gcg mRNA level via suppressing the promoter activity of gcg, hinting that TCF7L2 was responsible for the regulatory effect of β-catenin on gcg transcription. To evaluate whether miR-194 inhibited gcg transcription through TCF7L2, STC-1 cells were transfected with miR-194 inhibitor or miR-194 inhibitor+si-TCF7L2. The results of Fig. 3g and h showed that the interference of TCF7L2 reversed the promoting effect of the miR-194 inhibitor on GLP-1 level, gcg transcription, and the protein level of nuclear β-catenin, while not affecting the mRNA and protein levels of
PC1/3. In addition, in STC-1 cells transfected with miR-194 inhibitor, a great quantity of β-catenin was detected in complex pulled down by anti-TCF7L2, and the promoter activity of \( gcg \) was elevated (Fig. 3i). The above data indicating that miR-194 suppressed the activation of the Wnt/β-catenin pathway via negatively regulated TCF7L2 expression, thus inhibited the Wnt/β-catenin pathway-mediated \( gcg \) transcription.

**miR-194 reduced GLP-1 synthesis via repressing Foxa1-mediated \( pcsk1 \) transcription**

Following, we evaluated the effect of miR-194 on PC1/3 expression. As shown in Fig. 4a, in response to the overexpression of miR-194, the promoter activity of \( pcsk1 \) was markedly declined in IL-6-treated STC-1 cells. Meanwhile, Foxa1, a transcription factor that contributed to the GLP-1 production\(^{26}\), was also down-regulated after
miR-194 mimic transfection (Fig. 4b). Importantly, the luciferase activity of Foxa1 3'UTR was inhibited in the presence of miR-194 mimic (Fig. 4c). The silence of Foxa1 reversed the miR-194 inhibitor-induced high GLP-1 level, miR-194 inhibitor-up-regulated PC1/3, and miR-194 inhibitor-increased pcsk1 promoter activity, while didn’t
significantly change the gcg transcription (Fig. 4d and e), suggesting that miR-194 inhibiting pck1 transcription via targeting Foxa1, thus stopping PC1/3 from hydrolyzing proglucagon to GLP-1. Whereafter, we constructed the luciferase reporter plasmids containing the pck1 promoter regions between −2200 to 0 bp, −1500 to 0 bp, and −800 to 0 bp. The results of Fig. 4f showed that STC-1 cells transfected with the luciferase reporter plasmids containing the pck1 promoter region between −2200 to 0 bp and −1500 to 0 bp displayed reduced luciferase activity in response to the silence of Foxa1. Furthermore, CHIP assays showed that a great quantity of pck1 promoter region between −1500 to −800 bp was gathered in the complex pulled down by anti-Foxa1 (Fig. 4g), revealing that Foxa1 could bind to pck1 promoter at this region.

miR-194 mediated the cytotoxicity of PA on an L-like cell line via targeting TCF7L2

The PA level was significantly elevated in the feces of HFD-fed mice (Fig. 5a). The high concentration of PA (>0.5 mM) reduced cell viability and up-regulated miR-194 expression in the STC-1 cells (Fig. 5b and c). Since the miR-194 target genes, TCF7L2 and Foxa1, were proved to be involved in the regulation of cell growth27,28, we speculated that miR-194 may play a role in PA-induced cytotoxicity via regulating TCF7L2 and Foxa1. Notably, the interference of miR-194 reversed the inhibitory effect of PA on cell viability (Fig. 5d) and the protein levels of Foxa1, TCF7L2, and nuclear β-catenin, and removed the promoting effect of PA on c-caspase 3 protein level (Fig. 5e). Then, as shown in Figure 5f and g, in PA-treated STC-1 cells, the silence of miR-194 reduced PA-induced cell apoptosis, the si-TCF7L2, rather than si-Foxa1, abrogated the effect of miR-194 inhibitor, hinting that miR-194 participated in PA-induced apoptosis via targeting TCF7L2.

miR-194 knockdown induced GLP-1 synthesis in HFD-induced obese mice

To verify our in vitro findings in vivo, miR-194 was silenced in ileum tissues of HFD-induced obese mice utilizing intracolonic enemas of miR-194 antagomir (Fig. 6f). As depicted in Fig. 6a, b and c, oral glucose tolerance and insulin tolerance induced by HFD were relieved in miR-194 antagonist-treated mice compared with antagonist NC-treated mice. Meanwhile, miR-194 knockdown declined the body weight, islet area, and plasma levels of TG, TC and IL-6 in HFD-fed mice (Fig. 6d, j, and Table 3). In addition, the levels of GLP-1 in plasma, ileum, and colon were up-regulated by miR-194 antagonist (Fig. 6e and i). The high mRNA levels of gcg, pck1, TCF7L2, and Foxa1 in ileum and colon tissues of miR-194 antagonist-treated mice (Fig. 6g and h) displayed that miR-194 knockdown promoted GLP-1 synthesis via up-regulating TCF7L2/gcg and Foxa1/pck1.

Discussion

The major finding of the present study is that miR-194 functions to regulate GLP-1 synthesis in L cells. This conclusion was supported by the following distinct observations: (1) a negative correlation existed between plasma GLP-1 level and ileac miR-194 expression in HFD-induced obese mice; (2) miR-194 overexpression reduced GLP-1 level in IL-6-treated STC-1 cells via repressing transcriptions of gcg and pck1; (3) miR-194 knockdown reduced PA-induced cell apoptosis in STC-1 cells; (4) miR-194 knockdown relieved the metabolic symptoms caused by GLP-1 deficiency in HFD-induced obese mice.

MiRNAs have been reported to be involved in several metabolic diseases via negatively regulate gene expression at the post-transcriptional level by binding to the miRNAs29. For example, in type 2 diabetes mellitus (T2DM), miR-125a-5p was been reported to ameliorate hepatic glycolipid metabolism disorder through targeting signal transducer
and activator of transcription 3 (STAT3)\(^{30}\). Meanwhile, miR-148a proved to be a negative regulator of low-density lipoprotein receptor (LDLR) through targeting sterol regulatory element-binding protein 1\(^{31}\). Nevertheless, the studies focused on the role of miRNA in the synthesis of GLP-1, a pivotal regulator of glucose and lipid metabolism\(^{29}\), are still lacked. In the present study, an apparent up-regulation of miR-194 was observed in the obese mice model (Fig. 1c). The overexpression of miR-194 abolished the IL-6-induced high levels of GLP-1, gcg mRNA, and PC1/3 protein (Fig. 2e–g). The subsequent experiments clarified that the miR-194 suppressed gcg mRNA and PC1/3 protein via directly targeting TCF7L2 and Foxa1, respectively (Figs. 3 and 4). Our data thus firstly provide evidence that miR-194 could modulate GLP-1 production via transcription and protein levels.

Fig. 4 miR-194 reduced GLP-1 synthesis via repressing Foxa1-mediated pcesk1 transcription. a Promoter activity of pcesk1 and b mRNA and protein levels of Foxa1 were detected in IL-6- treated STC-1 cells which were transfected with miR-194 (0 or 50 or 100 nM). *P < 0.05 vs IL-6 treated cells. c The relative luciferase activity of Foxa1 3’-UTR was measured in the presence of miR-194 mimic or miRNC using the luciferase gene reporter assay. **P < 0.01 vs miRNC. d The active GLP-1 level, mRNA levels of gcg and pcesk1, the protein levels of Foxa1, PC1/3, and nuclear β-catenin, and e promoter activity of pcesk1 were measured in STC-1 cells which were transfected with miR-194 inhibitor or miR-194 inhibitor + si-Foxa1. **P < 0.01 vs untreated cells, ##P < 0.01 vs miR-194 inhibitor. f Luciferase activity associated with the region between −2200 to 0 bp, −1500 to 0 bp, and −800 to 0 bp of pcesk1 promoter in IL-6-treated STC-1 cells which were transfected with si-Foxa1. *P < 0.05 vs IL-6-treated cells. g Putative Foxa1 binding site in the region between −1500 to −800 bp of pcesk1 promoter. Chromatin immunoprecipitation (CHIP) followed by qRT-PCR was performed to evaluate the binding between Foxa1 and the pcesk1 promoter region between −1500 to −800 bp. The amount of DNA co-immunoprecipitated with each antibody was shown as relative to Input. **P < 0.01 vs Anti-IgG. h Mechanism diagram of Figs. 2 to 4.
Fig. 5 miR-194 mediated the cytotoxicity of PA on an L-like cell line via targeting TCF7L2. 

a The contents of palmitate (PA) from feces of mice in control and HFD groups were detected by chromatography. **P < 0.01. 

b, c The STC-1 cells were incubated with different concentrations of PA (0, 0.25, 0.5, 1, and 2 mM) for 24 h. The cell viability was measured by MTT assay. c The miR-194 expression was measured by qRT-PCR. *P < 0.05, **P < 0.01 vs control. 

d-e The STC-1 cells were transfected with miR-194 inhibitor and incubated with PA (1 mM). d Cell viability was measured by MTT assay. e The protein levels of TCF7L2, Foxa1, c-caspase 3, and nuclear β-catenin were measured by western blot. **P < 0.01 vs control; #P < 0.05, ##P < 0.01 vs PA. 

f, g After transfection of si-TCF7L2 or si-Foxa1 or miR-194 inhibitor or si-TCF7L2 + miR-194 inhibitor or si-Foxa1 + miR-194 inhibitor, STC-1 cells were incubated with PA (1 mM) for 24 h. f Cell apoptosis was measured by flow cytometry and the quantified results were shown in (g). *P < 0.05, **P < 0.01. 

h Mechanism diagram of Fig. 5.
Fig. 6 miR-194 knockdown induced GLP-1 synthesis in HFD-induced obese mice. Male C57BL/6 mice were divided into control (n = 6), HFD (n = 6), HFD + antagonim NC (n = 6), and HFD + miR-194 antagonim (n = 6) groups. 

a Oral glucose tolerance test (OGTT) was performed and the area of OGTT curve was measured (AUC).

b The plasma insulin level was determined by ELISA.

c The insulin tolerance test (ITT) was performed and the area of the ITT curve was measured (AUC).

d Body weight of mice in each group.

e The plasma level of active GLP-1 was assayed by ELISA.

f The miR-194 expression in ileum tissues was measured by qRT-PCR. The mRNA levels of gcg, pck1, TCF7L2, and Foxa1 were determined in ileum and colon tissues of mice. 

i Representative immunohistochemical staining for GLP-1 in ileum and colon tissues (scale bar=3 μm) and quantified results were expressed as the mean numbers of GLP-1-positive cells in HPFs.

j Representative H&E staining performed on pancreatic tissues (scale bar = 3 μm). 

*P < 0.05, **P < 0.01 vs control; aP < 0.05, #aP < 0.01 vs HFD + antagonim NC.
β-catenin is a key transcriptional coactivator of the canonical Wnt pathway, its accumulation in nuclear marks the activation of Wnt/β-catenin signaling pathway and enhanced the transcription of Wnt target genes. Ni et al. reported that ggc was among the target genes of the Wnt/β-catenin signaling pathway in GLUTag cells. Indeed, in our study, the high level of GLP-1 induced by IL-6 was associated with the up-regulation of nuclear β-catenin (Fig. 2b and g), and the silence of β-catenin suppressed the ggc mRNA level and reduced GLP-1 level (Fig. 3a). The previous study has proved that miR-194 could inactive Wnt/β-catenin signaling pathway via suppressing the nuclear accumulation of β-catenin, thus inhibiting cell invasion in hepatocellular carcinoma cells. Consistent with this, a decreased nuclear β-catenin expression was observed after miR-194 overexpression (Fig. 2). What’s more, our study also found that TCF7L2, a Wnt-transcription factor, was a direct target of miR-194 (Fig. 3d). As reported, in the absence of Wnt stimulus, cytoplasmic β-catenin combined with glycogen synthase kinase-3β and is then phosphorylated and ubiquitinated. When the Wnt signaling is activated, binding of Wnt to its receptors disrupts the β-catenin destruction complex and promotes the nuclear translocation of β-catenin. Then, nuclear β-catenin interacts with the T-cell factor (such as TC7F2) to transcriptionally regulate gene expression. Therefore, we speculated that miR-194 regulated Wnt/β-catenin signaling pathway-mediated ggc transcription via targeting TCF7L2. The subsequent experiments displayed that the silence of TCF7L2 removed the promoting effect of β-catenin on ggc promoter activity (Fig. 3e and f). In addition, in miR-194 silenced STC-1 cells, the combination between TC7F2 and β-catenin was promoted, resulted in an elevated ggc promoter activity (Fig. 3). These observations collectively showed that TC7F2 was responsible for the regulatory effect of the Wnt/β-catenin signaling pathway on ggc transcription and TC7F2 was a control point in the regulatory effect of miR-194 on ggc transcription.

Except for ggc, PC1/3 is also an indispensable participant during the progress of GLP-1 production. Foxa1 is a winged-helix transcription factor expressed in the definitive endoderm during embryogenesis and has been proved to be a contributor to the L cell differentiation. Baraille et al. found that the increased expression of Foxa1 led to an increase of GLP-1 plasma levels in mice while the mechanism remained unclear. In our study, we clarified that Foxa1 directly bound to the −1500 to −800 bp pcks1 promoter activity, thus enhancing pcks1 transcription (Fig. 4). Therefore, our study firstly illustrated the internal mechanism of the regulatory effect of Foxa1 on GLP-1 production and providing a new intervention target for GLP-1 synthesis.

It was previously reported that lipotoxicity, induced by PA, was able to reduce GLP-1 secretion and caused endoplasmic reticulum stress and apoptosis in L cell lines. In our in vitro experiment, we also observed that treatment with high PA concentrations (1 mM for 24 h) induced cell apoptosis of STC-1 cells (Fig. 5b). Of note, the miR-194 knockdown removed the proapoptosis effect of PA through targeting TCF7L2 (Fig. 5f and g). Therefore, we summarized that, except for directly regulated GLP-1 synthesis via targeting TCF7L2 and Foxa1, miR-194 could also indirectly repressed GLP-1 production by promoting PA-induced apoptosis of L cells.

In conclusion, the current study indicated that miR-194 suppressed GLP-1 synthesis via reducing TCF7L2-mediated ggc transcription and Foxa1-mediated pcks1 transcription. Additionally, miR-194 was also responsible for the PA-induced cell apoptosis in L cells. Our study firstly expounded the regulatory effect of miR-194 on GLP-1 synthesis in intestinal L cells, providing a novel target of treating metabolic syndrome caused by obesity.

Table 3 miR-194-5p antagomir on biochemical characteristics.

| Group                       | TG (mM)     | TC (mM)     | IL-6 (pg/ml) |
|-----------------------------|-------------|-------------|--------------|
| Control (n = 6)             | 1.07 ± 0.31 | 3.09 ± 0.57 | 112.58 ± 13.79 |
| HFD (n = 6)                 | 1.47 ± 0.25 | 5.49 ± 0.79 | 195.22 ± 19.42 |
| HFD + antagomir-NC (n = 6)  | 1.64 ± 0.34 | 5.64 ± 0.87 | 213.74 ± 18.08 |
| HFD + miR-194 antagomir (n = 6) | 1.21 ± 0.20 | 4.16 ± 0.83 | 166.11 ± 26.60 |

TC, total cholesterol; TG, triglyceride; HFD, high-fat diet; antagomir-NC, the negative control of miR-194 antagomir. *P < 0.05, **P < 0.01 vs control; #P < 0.05, ##P < 0.01 vs HFD + antagomir-NC.

Funding
This work was supported by grants from the Science and Technology Project of Henan Province (grant no. 192102310064 to J. Wang) and the National Natural Science Foundation of China (grant no. 81500646 to J. Wang), and this work was supported by the First Affiliated Hospital of Zhengzhou University.

Author contributions
Conceived and designed the study: J.W., D.Z., C.-Z.D, F.G. Performed the experiments: J.W., D.Z., C.-Z.D, F.G., L.-W., F.-JH., Y.-LL., S.-Y.Z., Y.X. Analysed the data: J.W., H.-F.J., X.W., L.-R.W. Wrote the paper: J.W., D.Z., C.-Z.D., F.G. All authors read and approved the final manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.

Ethics
All animal procedures were in accordance with institutional guidelines and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information accompanies this paper at (https://doi.org/10.1038/s41419-020-03366-0).

Received: 21 May 2020 Revised: 18 September 2020 Accepted: 9 October 2020
Published online: 21 January 2021

References
1. Seddell, J. C. & Halberstadt, J. The global burden of obesity and the challenges of prevention. Ann. Nutr. Metab. 66, Suppl 2:7–12 (2015).
2. Saelel, A. R. & Olefsky, J. M. Inflammatory mechanisms linking obesity and metabolic disease. J. Clin. Invest. 127, 1–4 (2017).
3. Doyle, M. E. & Egan, J. M. Mechanisms of action of glucagon-like peptide-1 in the pancreas. Pharm. Ther. 113, 546–593 (2007).
4. Flint, A., Raben, A., Astrup, A. & Holst, J. J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515–520 (1998).
5. Ellingsgaard, H. et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 17, 1481–1489 (2011).
6. Richards, P. et al. High fat diet impairs the function of glucagon-like peptide-1 producing L-cells. Peptides 77, 21–27 (2016).
7. Hayashi, H. et al. Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress. Metabolism 63, 800–811 (2014).
8. Xu, G. et al. Intestinal mTOR regulates GLP-1 production in mouse L cells. Diabetes Metab. 58, 1887–1897 (2015).
9. Zaoui, M., El Amri, H. & Bakillah, A. The clinical potential of adipogenesis type 2 diabetes mellitus through targeting of STAT3. Mol. Sci. 9, 1280 (2015).
10. Olio-Marston, S. E. et al. Effects of calorie restriction and diet-induced obesity on murine colon carcinogenesis, growth and inflammatory factors, and microRNA expression. PLoS ONE 9, e94765 (2014).
11. Nie, H., Pan, Y. & Zhou, Y. Eosomal microRNA-194 causes cardiac injury and mitochondrial dysfunction in obese mice. Biochem. Biophys. Res. Commun. 503, 3174–3179 (2018).
12. Nie, H. et al. MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. Biochem. Biophys. Acta Mol. Basis Dis. 1863, 3087–3094 (2017).
13. Timper, K. et al. IL-6 improves energy and glucose homeostasis in obesity via enhanced central IL-6 trans-signaling. Cell Rep. 19, 267–280 (2017).
14. Boden, G. Obesity, insulin resistance and free fatty acids. Curr. Opin. Endocrinol. Diabetes Obes. 18, 139–143 (2011).
15. Eisselte, R. et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Investig. 22, 283–291 (1992).
16. Filippello A. et al. Chronic exposure to palmitate impairs insulin signaling in an intestinal L-cell line: a possible shift from GLP-1 to glucagon production. Int. J. Mol. Sci. 19 (2018).
17. Chen, Z. et al. Inflammation-dependent downregulation of miR-194-5p contributes to human intervertebral disc degeneration by targeting CUL4A and CUL4B. J. Cell Physiol. 234, 19977–19989 (2019).
18. Castagliuolo, I. et al. Protective effects of neuropeptide-1 receptor during colitis in mice: role of the epidermal growth factor receptor. Br. J. Pharm. 136, 271–279 (2002).
19. Interfering with miR-24 alleviates rotenone-induced dopaminergic neuron injury via enhancing autophagy by upregulating DJ-1. Aging Pathol. Ther. 1, 17–24 (2019).
20. Gao, Y., Lui, W.-Y., Lee, W. M. & Cheng, C. Y. Polarity protein Crumbs homolog-3 (CRB3) regulates ectoplasmic specialization dynamics through its action on F-actin organization in Sertoli cells. Sci. Rep. 6, 28589–28589 (2016).
21. Ni, Z. et al. Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J. Biol. Chem. 278, 1380–1387 (2003).
22. Hou, N. et al. Transcription factor 7-like 2 mediates canonical Wnt/β-catenin signaling and c-Myc upregulation in heart failure. Circ. Heart Fail. 10.1161/CIRCHEARTFAILURE.116.003010 e003010. (2016).
23. Zheng, A. et al. Long non-coding RNA LUCAT1/miR-5582-3p/TCEF7L2 axis regulates breast cancer stemness via Wnt/beta-catenin pathway. J. Exp. Clin. Cancer Res. 38, 305 (2019).
24. Li, L., Yang, W. T., Zheng, P. S. & Liu, X. F. SOX17 restrains proliferation and suppression of apoptosis in osteosarcoma by regulating miR-212-3p/FOX1A axis. BioMed Res. Ther. 97, 1645–1653 (2018).
25. Wang, Z. et al. Salmonicin exerts anti-colorectal cancer activity by targeting the β-catenin/T-cell factor complex. Br. J. Pharm. 176, 3390–3406 (2019).
26. Capuani, B., Pacifici, F., Della-Morte, D. & Lauro, D. Glucagon Like Peptide 1 and MicroRNA in Metabolic Diseases: Focusing on GLP1 Action on miRNAs. Front Endocrinol. 9, 719–719 (2018).
27. Xu, L. et al. miR-125a-5p ameliorates hepatic glyc lipid metabolism disorder in type 2 diabetes mellitus through targeting of STAT3. Theranostics 8, 5593–5609 (2018).
28. Goeckele, L. et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat. Med. 21, 1280–1289 (2015).
29. Wang, N. et al. Activation of Wnt/β-catenin signaling by hydrogen peroxide transcriptionally inhibits NAD15 expression. Free Radic. Biol. Med. 96, 34–44 (2016).
30. Tang, H. et al. MicroRNA-194 inhibits cell invasion and migration in hepatocellular carcinoma through PRC1-mediated inhibition of Wnt/β-catenin signaling pathway. Digestive Liver Dis. 51, 1314–1322 (2019).
31. Emsris, G. et al. Chemoradiotherapy resistance in colorectal cancer cells is mediated by Wtntbeta-catenin signaling. Mol. Cancer Res. 15, 1481–1490 (2017).
32. Oloso, F. E. et al. Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell 125, 593–605 (2006).
33. Lee, J. H., Wen, X., Cho, H. & Koo, S. H. CREB/CRTC2 controls GLP-1-dependent regulation of glucose homeostasis. FASEB J. 32, 1566–1578 (2018).
34. Baralle, F. et al. Glucose tolerance is improved in mice invalidated for the nuclear receptor HNF4a, a critical role for enterocoiden cell lineage. Digest. 64, 2744–2756 (2015).
35. Filippello, A. et al. Chronic exposure to palmitate impairs insulin signaling in an intestinal L-cell line: a possible shift from GLP-1 to glucagon production. Int. J. Mol. Sci. 19, 3791 (2018).